- Home
- KPTI vs BCAB Comparison
KPTI vs BCAB Comparison
Compare KPTI & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- BCAB
- Stock Information
- Founded
- KPTI 2008
- BCAB 2007
- Country
- KPTI United States
- BCAB United States
- Employees
- KPTI N/A
- BCAB N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- KPTI Health Care
- BCAB Health Care
- Exchange
- KPTI Nasdaq
- BCAB Nasdaq
- Market Cap
- KPTI 33.6M
- BCAB 27.0M
- IPO Year
- KPTI 2013
- BCAB 2020
- Fundamental
- Price
- KPTI $4.21
- BCAB $0.32
- Analyst Decision
- KPTI Strong Buy
- BCAB Buy
- Analyst Count
- KPTI 5
- BCAB 2
- Target Price
- KPTI $61.00
- BCAB $1.00
- AVG Volume (30 Days)
- KPTI 172.5K
- BCAB 545.6K
- Earning Date
- KPTI 05-07-2025
- BCAB 05-13-2025
- Dividend Yield
- KPTI N/A
- BCAB N/A
- EPS Growth
- KPTI N/A
- BCAB N/A
- EPS
- KPTI N/A
- BCAB N/A
- Revenue
- KPTI $145,237,000.00
- BCAB $11,000,000.00
- Revenue This Year
- KPTI $4.87
- BCAB N/A
- Revenue Next Year
- KPTI $16.29
- BCAB N/A
- P/E Ratio
- KPTI N/A
- BCAB N/A
- Revenue Growth
- KPTI N/A
- BCAB N/A
- 52 Week Low
- KPTI $3.51
- BCAB $0.24
- 52 Week High
- KPTI $21.30
- BCAB $3.53
- Technical
- Relative Strength Index (RSI)
- KPTI 37.33
- BCAB 44.80
- Support Level
- KPTI $3.83
- BCAB $0.26
- Resistance Level
- KPTI $4.36
- BCAB $0.32
- Average True Range (ATR)
- KPTI 0.55
- BCAB 0.04
- MACD
- KPTI 0.13
- BCAB 0.00
- Stochastic Oscillator
- KPTI 25.64
- BCAB 39.50
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.